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End-organ resistance to growth hormone and IGF-I in epiphyseal
chondrocytes of rats with chronic renal failure
ROBERT H.K. MAK and YOUNGMI K. PAK
Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
End-organ resistance to growth hormone and IGF-1 in epiphyseal
chondrocytes of rats with chronic renal failure. We tested the hypothesis
that there is direct end-organ resistance to growth hormone (GH) and
IGF-I in chronic renal failure (CRF) independent of circulating inhibitors.
Male Sprague-Dawley rats underwent 5/6 nephrectomy and were pair-fed
with weight matched (100 g) sham operated controls for two weeks. Rats
with CRF had significantly higher serum creatinine and blood urea
nitrogen (P < 0.01 in both cases) and gained significantly less weight and
length (P < 0.01 in both cases) compared with controls. Epiphyseal
chondrocytes were grown in 10% fetal calf serum (FCS). Both CRF cells
and control cells maintained chondrogenic phenotypes, and showed
immunohistochemical staining with antibodies to collagen II and proteo-
glycan (aggrecan). Distribution of the cell subpopulations according to cell
size (by flow cytometry) and alkaline phosphatase activity of CRF and
control chondrocyte cultures were not different. Growth responses of CRF
chondrocytes were reduced (P < 0.01) compared with control chondro-
cytes when grown in 10% FCS and 10% normal rat serum. Under serum
free conditions, growth responses of CRF chondrocytes were reduced to
GH and IGF-I at concentrations of 10, 30 and 100 ng/ml, and to insulin at
100, 300 and 1,000 ng/mt compared with controls cells (P < 0.01). To show
that this resistance is specific for the GH/IGF system, growth responses to
fibroblast growth factor and transforming growth factor /31 were studied
and showed no difference between CRF and control cells. Thus, the
present study provides direct evidence of specific end-organ resistance to
GH, IGF-I in CRF chondrocytes in the absence of circulating factors.
Increased GHBP has been shown in CRF rats and may be
involved in the pathogenesis of GH resistance in CRF by com-
peting for ligand binding to the GH receptor [31. Increased serum
IGF binding capacity as well as increased serum IGFBP-1 and
IGFBP-3 are present in children with CRF [4]. Removal of these
excessive IGFBPs from CRF sera by affinity chromatography
resulted in a significant increase in IGF bioavailability by cartilage
explant sulfate incorporation. IGF resistance in CRF may there-
fore be due to the presence of excess circulating IGFBPs [4, 5].
However, Martin et a! showed that supraphysiological doses of
IGF-I and des-IGF-I (an analogue with reduced affinity for the
IGFBP5) can equally correct growth retardation in rats with CRF,
suggesting that there may be end-organ resistance to IGF-I
independent of circulating IGFBPs [6].
The present study tests the hypothesis that there is direct end
organ resistance to GH and IGF-I independent of circulating
inhibitors in a rat model of CRF. We use a primary culture of
epiphyseal chondroyctes to study growth stimulating effects of
individual growth factors in the absence of other serum factors on
the cells that account for longitudinal growth.
Methods
Experimental model
Growth retardation is a serious consequence of chronic renal
failure (CRF) in childhood. The pathogenesis is clearly mutifac-
tonal including nutritional, electrolyte and hormonal distur-
bances. Attempts at correcting nutritional and electrolyte distur-
bances have failed to normalize growth in CRF [1]. A recent
report from the North American Pediatric Renal Transplant
Cooperative study showed that the mean baseline height of over
a thousand children with CRF was below two SD scores at the time
of transplantation [2]. This indicates that growth retardation
continues to be an unresolved consequence of CRF despite
optimal clinical management.
Circulating levels of GH and IGF-I are normal in children with
CRF despite growth retardation suggesting resistance to these
growth factors. Current evidence suggests that resistance to these
growth factors in CRF are due to circulating inhibitors and that
these inhibitors may be in the form of binding proteins (BP).
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Male Sprague-Dawley rats weighing between 85 to 90 g were
purchased from Charles River Laboratories (Wilmington, MA,
USA) and housed in an environmentally controlled room with a
12 hour light/dark cycle, where they had free access to standard
rat chow (Wayne MRH 22/5 Rodent Blox 8640) containing 22.2%
protein and 0.36% sodium. After three days of equilibration in the
new environment, CRF was induced in the animals by 5/6
nephrectomy in a one stage procedure. Under anesthesia (intra-
peritoneal pentobarbital 50 mg/kg) approximately two-thirds of
one kidney was removed through a flank incision. When hemo-
stasis was achieved, the contralateral kidney was then removed in
through another flank incision under the same anesthesia in a one
stage procedure. Each control animal was matched for weight
with an uremic animal and underwent the same anesthesia and
sham operation (decapsulation of the kidneys) a day later. All
animals were housed in individual cages and were pair-fed. The
CRF rats were fed ad libitum. Daily food intake of CRF rats was
measured and the same amount of food was given to the allocated
paired sham control the following day. The total period of
observation was two weeks, at the end of which the animals were
sacrificed by an overdose of sodium pentobarbital. The snout to
tail lengths were measured at the time of nephrectomy and
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sacrifice, in both instances under anesthesia so that the animals
were totally relaxed. Blood was taken for measurement of serum
creatinine and blood urea nitrogen. Both knee joints were dis-
sected out under sterile conditions. All data points were derived
from six independent experiments. Each data point in these
independent experiments was derived from cells from two rats
(either 2 control rats or 2 CRF rats). The total number of rats in
six independent experiments were 24 (12 control rats and 12 CRF
rats).
Primaiy epiphyseal chondrocyte culture
Cartilage from rat tibial growth plate was dissected under
sterile conditions and placed in a petri dish with Dulbecco's
modified Eagles medium (DMEM) with 50 g/ml gentamicin and
minced with a scalpel. Bacterial collagenase (Type II and IV,
Worthington Biochemicals, Freewood, NJ, USA) were added a
final concentration of 0.6 mg/mI and the mixture was incubated
overnight at 37°C in 7.5% CO2 and 100% humidity. The cells were
then collected, washed with phosphate buffered saline (PBS) and
filtered though a 100 m polypropylene mesh. Cell number was
determined by counting on a hemocytometer and viability was
determined by tryphan blue dye exclusion. In each isolation, cells
from two rats per group were pooled with a cell yield of 3 to 5 X
i05 cells per rat and viability was over 90%. This cell yield was
similar to the one reported previously by Ohlsson et al [7].
Subsequently, cells were suspended in complete media: 1:1 mix-
ture of DMEM and Ham's F12 supplemented with gentamicin
and either 10% control rat serum or 10% fetal calf serum (FCS).
First, the cells were seeded in 24 well plates at a density of 4 X i04
cells per well and growth responses (MTT, thymidine incorpora-
tion and cell number) were assessed after 72 hours of incubation
with the complete medium containing 10% control rat serum.
Then, 5 X iO cells were seeded in 100 mm culture dishes and cell
number was assessed after seven days of incubation with the
complete medium containing 10% FCS. Culture media were
changed every three days in the latter experiment.
For studies relating to growth responses to different growth
peptides the cells were seeded in 24 well plates coated with
poly-L-lysine at a density of 4 X iO' cells per well and allowed to
attach to the plate in 10% FCS for 24 hours. Then they were
incubated with serum free medium (SFM), which is a 1:1 mixture
of DMEM and Ham's F12 supplemented with gentamicin, 20 nM
selenium and lipid emulsion containing lecithin, cholesterol,
sphingomyelin, vitamin E and vitamin E acetate, for 48 hours
before the test peptides (human recombinant IGF-I, Genentech
mc, San Francisco, CA; human recombinant insulin, Eli Lily mc,
Indianapolis, IN, USA) in different concentrations were added
into each well and further incubated for 72 hours. The incubation
period with the test peptide was increased to 96 hours for studies
relating to GH (human recombinant GH; Genentech Inc.) growth
responses. For growth assessment, cell number, 3H-thymidine
incorporation and mitogenic activity using methyithiazol tetrazo-
hum (Mfl') [8] were determined.
Immunohistochemistiy
Chondrocytes were cultured in complete medium with 10%
FCS on sterile glass cover slips until 80 to 90% confluent. They
were then fixed in 1:1 mixture of acetone/methanol for 10 minutes
and then stained with rabbit antibovine collagen type II and rabbit
anti-bovine proteoglycan (aggrecan) antiserum (generous gift of
Dr. R.L. Smith, Functional Restoration, Stanford University).
Goat anti-rabbit IgG (H+L) conjugated with alkaline phos-
phatase (Bio-Rad, CA, USA) was used as a second antibody and
developed with nitro blue tetrazolium (NBT) and 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP) substrates.
Flow cytomety
Cells were trypinized, counted, washed and resuspended in
complete media with 10% FCS. Flow cytometry was used to
measure distribution of cell subpopulations according to cell size.
Forward light scatter was measured on a FACSTAR flow cytom-
eter (Becton-Dickinson).
Alkaline phosphatase activity
A soluble protein extract of cells was obtained using 0.1%
Triton X-100 (10 mM Tris-HCI, pH 7.4) for 60 minutes at 4°C.
Enzyme activity was assayed in 100 j.Ll aliquots by measuring the
release of p-nitrophenol from the substrate p-nitrophenyl phos-
phate disodium (Sigma: Technical Bulletin 104) and then assessed
by spectrophotometry at 405 nm. Protein content of the CRF and
the control chondroyctes was measured by the Bio-Rad DC
protein assay and the alkaline phosphatase activity was expressed
as mol/min/mg protein.
Methyl thiazol tetrazolium (MTT) mitogenic activity assay
Chondrocytes were seeded on 96 well plates at the density of
10,000 cells per well. The desired concentrations of reagents were
added in each well and incubated for 72 hours at 37°C, 7.5% CO2.
The assay mixture containing C3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) was added into each well
and incubated under the same conditions for four hours. Purple
precipitates generated by live cells were extracted with HC1/
isopropanol and the optical density of each well was determined
using ELISA plate readers (Bio-Rad) at 570 nm [8].
3H-thymidine incorporation
Chondrocytes grown on 24 well plates were labeled with 5
Ci/ml 3H-thymidine (New England Nuclear, MA, USA) per well
for 18 hours before terminating the reaction. The media were
removed and the cells were washed with PBS. DNA was precip-
itated with 10% TCA at 4°C, redissolved in NaOH and the
incorporated radioactivity was counted.
Statistics
All data points were derived from six independent experiments.
Each data point in these independent experiments was derived
from cells from two rats (either 2 control rats or 2 CRF rats). The
total number of rats in six independent experiments were 24 (12
control rats and 12 CRF rats). The data were tested for normality
by the chi square test and then analyzed for statistical difference
using the unpaired t-test. Bonferroni correction was made for
multiple t-tests when different methods were used to measure
growth responses. Analysis of variance with the Student-Newman-
Keuls test was performed for comparing growth responses to
different concentrations of peptides.
Results
The weights and lengths as well as the dietary intakes in the
control and CRF rats are presented in Table 1. Rats with CRF
and control rats were not different in initial weights and lengths.
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Table 1. Growth, serum chemistiy and food intake of the CRF and control rats
Initial
weight
Weight
gain
Initial
length
Length
gain
Serum
creatinine BUN
Food
intake
g
Caloric
intake
KcalGroup g cm mg/dl
CRF (N = 12) 99.1 2.1 32.2a 7.1 27.4 0.5 4.3k' 0.4 0.T 0.1 35.8 4.4 141 6 563 24
Sham(N= 12) 99.7±2.2 57.5±4.3 27.0±0.3 6.3±0.7 0.4±0.1 12.5±1.3 141±6 563±24
Data are mean SD. The serum creatinine and BUN measurements were made at the end of the study.
ap < 0.01
0 200 400 600
Over the two-week experimental period, rats with CRF consumed
equal amounts of food as compared with the controls but gained
significantly less weight (56% of control values, P < 0.01) and
length (68% of control values, P < 0.01). The rats with CRF also
had higher serum creatinine and blood urea nitrogen (P < 0.01 in
both cases). The degree of renal insufficiency in the rats in the
present study is only modest compared with other studies using
5/6 nephrectomy protocols [9]. Nonetheless, the CRF rats were
growth retarded compared with sham-operated pair-fed controls.
To demonstrate that both CRF and control epiphyseal chon-
drocytes maintain their chondrogenic phenotype in primary cul-
ture, immunohistolochemical staining of the cells grown on cover
slides was performed with antibodies to proteoglycan and collagen
II revealing positive results in both CRF and control cell cultures.
To investigate the possibility that the primary cultures of CRF and
control chondrocytes contain different subpopulations of cells,
distribution of the subpopulations according to cell size was
studied by flow cytometry. The forward scatters of CRF and
control chondrocytes are almost identical (Fig. 1). Also the
alkaline phosphatase activity of the two cell populations was
measured and there was no difference between CRF cells (6.13
0.14 mol/min/mg protein) and control cells (5.87 0.59 j.mol/
mm/mg protein).
The growth responses of CRF and control chondrocytes to
different concentrations of normal rat serum were then studied
using the MYF test. Figures 2A shows that the growth responses
of CRF chondrocytes are significantly reduced (P < 0.05) com-
pared with control chondrocytes at 10% concentration of normal
rat serum. The growth responses were then measured again, by
thymidine incorporation and cell number. The results are shown
in Figure 2 B (thymidine incorporation) and C (cell number),
indicating that the growth responses of the CRF chondrocytes to
10% normal rat serum are reduced compared with control
chondroyctes (P < 0.05 in both cases; Bonferroni correction was
performed for multiple t-tests). Similarly, growth (cell number) of
CRF chondrocytes in the presence of 10% FCS is also much
reduced compared with control chondroyctes (P < 0.01, Fig. 3).
The growth responses of the chondrocytes to various growth
factors in serum free media were studied and the results are
shown in Figure 4. Growth responses of CRF chondrocytes to GH
in serum free media at 1, 10, 30 and 100 ng/ml concentrations are
reduced compared with control chondrocytes (P < 0.01 in all 3
800 cases) indicating growth hormone resistance. Growth responses ofCRF chondrocytes to IGF-I in serum free media are also reduced
at 1, 10, 30 and 100 ng/ml concentrations compared with control
chondrocytes (P < 0.01) indicating IGF-I resistance. At low
concentrations of insulin at 1 and 10 ng/ml (which did not
significantly stimulate growth in control chondrocytes), there are
no differences in the growth responses between the two different
cell types. However, growth responses of CRF chondrocytes to
insulin in serum free media at 100, 300 and 1,000 nglml are
reduced compared with control chondrocytes (P < 0.01). Since
these insulin concentrations are supraphysiological and are more
likely to involve the IGF type I receptor, this provides further
evidence of IGF-I resistance. To demonstrate that the resistance
to growth stimulation in CRF chondrocytes is specific for the
GH/IGF system, growth responses to fibroblast growth factor
(FGF) and transforming growth factor (TGF) /31 were studied.
There are no significance differences between CRF and control
chondrocytes in terms of their growth responses to FGF and TGF
/31 over a range of concentrations shown in preliminary studies to
effectively stimulate normal chondrocyte growth. These results are
shown in Figure 5. Finally, these chondrocytes only maintained
their impaired responsiveness to serum and growth factors for two
passages. This phenotype was not present after one month of
culture.
Discussion
A critical function of the epiphyseal chondrocytes is the pro-
duction of cartilage matrix, primarily composed of cartilage
collagens and proteoglycans. Type II collagen is the predominant
structural collagen of cartilage and the distinguishing collagen
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Fig. 1. Forward scatters of the GRE and control chondrocyte cultures as
measured on a FACSTAR flow cytometer.
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Fig. 2. Effect of 10% control rat serum on growth over a three days period of chondrocytes from CRF and control rats as measured by the MTT test (A),
3H-thymidine incorporation (B) and cell number (C). N = 6 independent experiments, that is, 12 rats per group. Data are mean SD; *P < 0.05 by
unpaired t-test with Bonferroni adjustment; CRF vs. control.
Fig. 3. Effect of 10% FCS on growth over a seven days period of chondro-
cytes from CRF and control rats as measured by cell number. N = 6
independent experiments, that is, 12 rats per group. Data are mean si;
'P < 0.01 by unpaired t-test, CRF vs. control.
type synthesized by chondrocytes [101. Studies employing histo-
chemical methods have suggested that type II collagen is homog-
enously distributed throughout the growth plate [11]. The char-
acteristic proteoglycan produced by chondroyctes is aggrecan, a
large aggregating proteoglycan substituted with up to 100 chon-
droitin sulfate chains. The synthesis of type II collagen coupled
with the synthesis of aggrecan traditionally defines the chondro-
cyte phenotype [81. In the present study, the demonstration of
both collagen II and aggrecan by immunohistochemistry in epiph-
yseal chondrocytes from both CRF and control rats grown in
monolayers indicate that these cells are differentiated chondro-
cytes. This is in agreement with previous studies by Ohlsson et al
demonstrating that rat epiphyseal chondrocytes in primary mono-
layer cultures maintain their chondrogenic phenotype up to 15
days [7].
In the normal growth plate, chondrocytes undergo a series of
developmental changes in structure and function through the
resting, proliferative, maturing and hypertrophic zones before
calcification occurs. Alini et al [121 showed that bovine fetal
epiphyseal chondrocytes can be divided into five subpopulations
according to cell density and size (from the smallest resting cells
to the largest hypertrophic cells). Alkaline phosphatase activity
correlates with cell size in these bovine fetal chondrocytes [131.
There are no corresponding data in rats to date. In vitro studies
using mixtures of growth plates chondrocytes have produced
conflicting results as to how these cells respond to different growth
factors and hormones. This is probably because the responses of
chondrocytes from different regions of the growth plates are
dependent upon their maturational state. Also, mixed cultures
may contain varying proportions of different cells in different
maturational and responsive states. The growth plate in CRF rats
is altered [9]. It is therefore possible that the differences in growth
responses of the CRF chondrocytes is not related to the renal
insufficiency but to the selection of different chondrocyte sub-
populations. However, the distribution of the cell subpopulations
according to cell size in CRF and control chondrocyte cultures as
studied by flow cytometry were almost identical. Also the alkaline
phosphatase activity was not difference between CRF cells and
control cells. Thus differences in different chondrocyte subpopu-
lations are not the likely cause of growth response differences
between CRF and control epiphyseal chondrocyte cultures in the
present study.
In 10% normal rat serum, the growth responses of CRF
chondrocytes are significantly reduced compared with control
chondrocytes. These growth responses have been measured by
three different methods which yield the same results. Further-
more, this phenomenon is confirmed by the growth responses of
the chondrocytes in 10% FCS. This is in agreement with the
clinical data that the rats with CRF are growth retarded compared
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Fig. 4. Effect of (A) GH, (B) IGF-I and (C) insulin on the growth of chondrocytes from CRF (4-) and control (-LII-) rats. The primary cells from each
group were seeded on 24-well plates at a density of 4 X io and grown in the presence of complete media to allow the cells to attach to the plate. Then
the cells were serum-starved for 48 hours. Different concentrations of GH were added to each well and incubated with the cells for 96 hours. Different
concentrations of IGF-I and insulin were added to each well and incubated with the cells for 72 hours. The cells were then harvested by trypsinization
and the cell numbers were determined with a hemocytometer. N = 6 independent experiments, that is 12 rats per group, data = mean SD. Growth
responses of CRF chondrocytes to GH at 1, 10, 30 and 100 ng/ml concentrations are reduced compared with control chondrocytes (P < 0.01 in all cases).
Growth responses of CRF chondrocytes to IGF-I in serum free media are also reduced at 1, 10, 30 and 100 nglml concentrations compared with control
chondrocytes (P < 0.01 in all cases). At low concentrations of insulin at 1 and 10 nglml, there are no differences in the growth responses between the
two different cell types. However, growth responses of CRF chondrocytes to insulin in serum free media at 100, 300 and 1,000 ng/ml are reduced
compared with control chondrocytes (P < 0.01). p < 0.01 by analysis of variance followed by the Student-Newman-Keuls test at all higher
concentrations, CRF versus control.
Fig. 5. Effect of (A) FGF and (B) TGF /31 on
the growth of chondrocytes from (.4) CRF and(-s-) control rats. The primary cells from each
group were seeded on 24-well plates at a
density of 4 X iO and grown in the presence of
complete media to allow the cells to attach to
the plate. Then the cells were serum-starved for
48 hours. Different concentrations of FGF (10,
30, 100 and 250 nglml) and TGF /31(0.01, 0.1,
0.5 & 1 ng/ml) were added to each well and
incubated with the cells for 72 hours. The cells
were then harvested by trypsinization and the
cell numbers were determined with a
hemocytometer. N = 6 independent
experiments, that is, 12 rats per group. Data are
mean SD. No significant difference was found
1 1 .25 at all concentrations by analysis of variance
followed by Student-Newman-Keuls test, CRF
versus control.
with the pair-fed sham operated controls. Thus the chondrocytes differentiating cells in the growth plate of the long bones. Growth
from rats with CRF maintain the phenotype of growth retardation hormone (GH) stimulates longitudinal bone growth in a dose-
in primary culture. dependent manner [14]. GH receptors have been demonstrated in
Longitudinal bone growth is the result of recruitment of cells rat epiphyseal chondrocyte cultures [151. However, the stimula-
from the stem cell layer and subsequent proliferation of the tory effect of GH is dependent on the presence of IGF-I [16].
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GH-dependent IGF-I peptide immunoreactivity has been shown
in the growth plates of hypophysectomized rats [17]. Insulin, in
high concentrations, can compete for binding to the IGF type I
receptor [18] and promotes proliferation in primary chondrocyte
culture [19, 20]. Ohlsson et a! [7] have previously shown that the
time course for the stimulatory effect of GH and IGF-I on
proliferation of epiphyseal chondrocytes grown in primary mono-
layer cultures are different. GH effects become significant after
three days of culture whereas IGF-I effects are apparent during
the first 24 hours of culture. Similar observation was obtained in
our laboratory. Therefore the GH dose responses in the present
study were performed with a longer incubation period with the
test peptide in the present study. The concentrations of GH and
IGF-I used in the dose response studies are within physiological
range under serum free conditions in chondrocyte culture systems
[7]. The maximum stimulatory effects of GH (—300%) and IGF-I
(—450%) on control chondrocytes are similar to those reported
previously by Ohlsson et al [7]. The maximum stimulatory effects
of GH and IGF-I on CRF chondrocytes are much reduced
(—150%) compared with control chondrocytes, indicating end-
organ resistance in the GH/IGF axis in CRF. The concentrations
of insulin (100 to 1,000 ng/ml or 2400 to 24,000 tU/ml) used are
24 to 240 times higher than insulin concentrations (around 100
jiU/ml) achieved in humans during hyperglycemic stimuli. These
concentrations are not physiological but have been reported to be
competitive for binding to the IGF type I receptor and to
stimulate chondrocyte matrix formation and proliferation [19, 20].
Therefore the insulin effects observed in the present study are
likely to be related to the IGF type I receptor and not the insulin
receptor. Two other growth factors are known to stimulate
proliferation of chondrocytes in culture, namely FGF and TGF 131
[21]. The demonstration of responsiveness of CRF chondrocytes
to FGF and TGF 131 indicates that the end-organ resistance to
growth stimulation in CRF is specific for the GH!IGF axis.
The present study provides, for the first time, direct evidence of
end organ resistance of epiphyseal chondrocytes to GH, IGF-I
and insulin in CRF. In all previous studies of GH and IGF-I
effects on longitudinal growth in CRF [6, 91, these peptides were
administered to whole animals and therefore the effects of these
peptides on overcoming circulating inhibitors in CRF such as
elevated GHBP and IGFBPs were likely mechanisms. Mehls Ct al
[9] treated CRF rats with supraphysiological doses of growth
hormone for 14 days and achieved partial correction of their
growth retardation. However, this was not accompanied by an
increase in circulating IGF-I. The authors concluded that this
constituted evidence of in vivo growth hormone resistance. Ton-
shoff et al demonstrated elevated circulating GHBP in CRF rats
and postulated that this may be an inhibitor of GH action in CRF
by competing for ligand binding to the receptor [3]. IGF-I
resistance in uremic children could also be due to increased serum
concentration of IGFBPs despite normal serum IGF-I concentra-
tions [221. Treatment of uremic children with GH improved the
ratio between the serum concentrations of IGF-I and IGFBP and
normalized the somatomedin bioactivity (measured by growth
cartilage bioassay) of the sera from these patients [22].
There is indirect evidence to support end-organ resistance to
GH and IGF in CRF. Chan, Valerie and Chan demonstrated
decreased induction of hepatic IGF-I mRNA by GH in CRF rats
and that it was accompanied by decreased hepatic GH receptor
mRNA. The authors postulated that the GH resistance in CRF
rats was partially due to decreased hepatic GH receptor at the
transcription level [23]. Finidori et al showed reduced growth
hormone binding in the liver of CRF rats [24]. Tonshoff et al also
demonstrated decreased hepatic GH receptor mRNA in CRF rats
and postulated that it might contribute to GM resistance in CRF
[3]. There were no measurements of GH receptor peptide expres-
sion in these studies. Also, there are no studies to date on GH
receptor peptide or mRNA expression in growth plates in CRF.
Martin et al [61 administered supraphysiological doses of IGF-I to
CRF rats and showed improved growth. They also demonstrated
the growth responses of CRF rats to des-IGF (an analogue of
IGF-I with reduced affinity to IGFBPs) were similar to the
responses to equivalent doses of IGF. This provides indirect
evidence that there is end-organ resistance to IGF-I independent
of circulating IGFBPs since the responses to des-IGF would be
expected to be much enhanced if elevated IGFBPs was the main
mechanism of growth retardation.
Insulin resistance and hyperinsulinemia are common in chil-
dren with CRF [25] and may be important in the pathogenesis of
growth retardation. Growth velocity SD scores in children with
CRF have been shown to correlate with the insulin secretion
during hyperglycemia [26]. McCaleb et al have partially purified
and characterized a factor from uremic sera that inhibits insulin-
mediated glucose disposal in normal rat adipocytes [27]. However,
the insulin resistance observed in the present study is at supra-
physiological dose ranges and is therefore likely to be at the IGF
type I receptor level rather than at the insulin receptor level. Since
insulin does not bind to IGFBPs at all, this provides further
evidence of end organ resistance at the IGF type I receptor level
independent of IGFBPs.
Thus the present study provides direct evidence of end organ
resistance to GH, IGF-I and insulin of epiphyseal chondrocytes in
CRF. The mechanism of resistance to GH and IGF-I shown in
these in vitro studies in the absence of CRF serum indicates that
circulating inhibitors are not involved. However, this does not
exclude contributions from serum factors in the in vivo situation.
The primary cell culture system described in the present study
provides a good in vitro model to study underlying mechanisms
involved in the growth retardation of CRF.
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